Smith+Nephew’s OXINIUM™ Technology recognized as the best performing bearing with lowest risk of revision in total hip arthroplasty
LONDON, Aug. 30, 2021 /PRNewswire/ — Smith+Nephew (LSE:SN,NYSE:SNN), the global medical technology business, today announces its proprietary OXINIUM (Oxidized Zirconium) Technology has established itself as the best performing bearing with the lowest risk of revision in total hip arthroplasty (THA)1-4, alongside similarly strong clinical performance in knees.5 These results are substantiated by four national and regional joint registries1-4 over the last 20 years with more than 2 million procedures4 to draw from.
Through a unique manufacturing process, the zirconium alloy material transforms and hardens through oxidation. OXINIUM (Oxidized Zirconium) becomes a ceramicised metal – a true material transformation – rather than an applied coating.6 It is this material transformation that provides OXINIUM with its ground-breaking performance benefits which include:
Proven clinical performance:
- OXINIUM delivers the lowest risk of revision at 10 years14,15 across data from four national and regional joint registries for total hip arthroplasty, providing improved survivorship against both metal and ceramic bearings.1-4
- In total knee arthroplasty, implants powered by OXINIUM perform at A/A* levels according to ODEP up to 15 years, providing excellent survivorship.5
Unrivalled material properties:
- OXINIUM Oxidized Zirconium represents a step change for implant technology combining the durability of metal,6,7 the wear and biocompatibility of ceramic8-12 and corrosion resistance better than both.13,14
- OXINIUM contains virtually undetectable levels of nickel, cobalt and chromium and shows a lower pro-inflammatory cytokine expression compared to cobalt-chrome in vitro.11,12,15
Established economic performance across the episode of care:
- Analysis of Medicare claims data, controlling for patient population, has shown that OXINIUM hips and JOURNEY II with OXINIUM Technology can deliver savings as part of an episode of care associated in part with lower readmission rates.16,17
Ideal for Revisions:
- The material properties of OXINIUM coupled with the design elements of LEGION™ Revision Knee System, LEGION HK Hinge Knee, OR3O™ Dual Mobility System and REDAPT™ Revision Hip System can bring benefits to revision patients.
“OXINIUM addresses multiple risks…the first being longevity. Patients don’t want to get re-operated on and the idea that OXINIUM implants can last longer and has better wear properties is important”, said Dr. Steven B. Haas, Chief of the Knee Service at Hospital for Special Surgery. “The second big one is that it has virtually no nickel and is biocompatible, because patients are concerned about this.”
“I think the most important thing to understand is that OXINIUM is not a coating – it’s a material transformation. And it makes the material a better material, a better solution,” said Dr. Thorsten Seyler, Assistant Professor of Orthopaedic Surgery at Duke University. “It’s a very attractive solution with excellent wear properties for young and active patients in terms of longevity of an implant. It also offers revision solutions for the really challenging cases.”
Smith+Nephew is the only company in the world able to offer this unique implant material in total joint replacement procures. To learn more about OXINIUM, please stop by the Smith+Nephew booth (#1735) during AAOS 2021.
- Davis ET, Pagkalos J, Kopjar B. Bearing surface and survival of cementless and hybrid total hip arthroplasty in the National Joint Registry of England, Wales, Northern Ireland and the Isle of Man. JBJS. 2020;5(2):pe0075.
- Peters RM, Van Steenbergen LN, Stevens M, et al. The effect of bearing type on the outcome of total hip arthroplasty. Acta Orthopaedica. 2018; 89(2):163-169.
- Atrey A, Ancarani C, Fitch D, Bordini B. Impact of bearing couple on long-term component survivorship for primary cementless total hip replacement in a large arthroplasty registry. Poster presented at: Canadian Orthopedic Association; June 20–23, 2018; Victoria, British Columbia, Canada.
- Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR) Hip, Knee & Shoulder Arthroplasty: 2020 Annual Report.
- The Orthopaedic Data Evaluation Panel (ODEP). www.odep.org.uk. Accessed June 1st, 2021.
- Hunter G, Dickinson J, Herb B, et al. Creation of oxidized zirconium orthopaedic implants. Journal of ASTM International. 2005;2:1-14.
- Long M, Riester L, Hunter G. Nano-hardness Measurements of Oxidized Zr-2.5Nb and Various Orthopaedic Materials. Abstract presented at: 24th Annual Meeting of the Society for Biomaterials. April 22-26, 1998, San Diego, California.
- Parikh A, Hill P, Pawar V, Sprague J. Long-term Simulator Wear Performance of an Advanced Bearing Technology for THA. Poster presented at: 2013 Annual Meeting of the Orthopaedic Research Society. Poster no. 1028.
- Papannagari R, Hines G, Sprague J, Morrison M. Long-term wear performance of an advanced bearing technology for TKA. Poster presented at: 2011 Annual Meeting of the Orthopaedic Research Society. Poster no. 1141.
- Smith+Nephew 2010. OR-10-155.
- Dalal A, Pawar V, McAllister K, Weaver C, Hallab NJ. Orthopedic implant cobalt-alloy particles produce greater toxicity and inflammatory cytokines than titanium alloy and zirconium alloy-based particles in vitro, in human osteoblasts, fibroblasts, and macrophages. J Biomed Mater Res Part A. 2012;100A:2147-2158.
- Hallab NJ, McAllister H, Jacobs JJ, Pawar V. Zirconium-alloy and zirconium-oxide particles produce less toxicity and inflammatory cytokines than cobalt-alloy and titanium-alloy particles in vitro, in human osteoblasts, fibroblasts and macrophages. Annual Meeting of the Orthopaedic Research Society (ORS), 2012. San Francisco, CA.
- Aldinger P, Williams T, Woodard E. Accelerated Fretting Corrosion Testing of Zirconia Toughened Alumina Composite Ceramic and a New Composition of Ceramicised Metal Femoral Heads. Poster presented at: 2017 Annual Meeting of the Orthopaedic Research Society. Poster no. 1037.
- Smith+Nephew 2016. OR-16-127.
- ASTM International Standard Specification for Wrought Zirconium-2.5 Niobium Alloy for Surgical Implant Applications (UNS R60901) Designation: F 2384 – 10.
- Patrick C, Delhougne G, Patel A. Retrospective Analysis of Oxidized Zirconium Bearing Surface in Hip Replacement 90-Day Episode Claims. ISPOR EU Poster, 2019.
- Mayman DJ, Patel AR, Carroll KM. Hospital related clinical and economic outcomes of a bicruciate knee system in total knee arthroplasty patients. Poster presented at: ISPOR Symposium; May 19-23, 2018; Baltimore, Maryland, USA.
Smith+Nephew is a portfolio medical technology business that exists to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 18,000 employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Advanced Wound Management and Sports Medicine & ENT.
Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $4.6 billion in 2020. Smith+Nephew is a constituent of the FTSE100 (LSE:SN,NYSE:SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.
For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on Twitter, LinkedIn, Instagram or Facebook.
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as “aim”, “plan”, “intend”, “anticipate”, “well-placed”, “believe”, “estimate”, “expect”, “target”, “consider” and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: risks related to the impact of COVID-19, such as the depth and longevity of its impact, government actions and other restrictive measures taken in response, material delays and cancellations of elective procedures, reduced procedure capacity at medical facilities, restricted access for sales representatives to medical facilities, or our ability to execute business continuity plans as a result of COVID-19; economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers (including, without limitation, as a result of COVID-19); price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers (including, without limitation, as a result of COVID-19); competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew’s most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew’s expectations.
™ Trademark of Smith+Nephew. Certain marks registered US Patent and Trademark Office.
SOURCE Smith & Nephew plc